Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Exchange Rate Effect (2023 - 2025)

Rein Therapeutics has reported Exchange Rate Effect over the past 3 years, most recently at -$18000.0 for Q4 2025.

  • Quarterly Exchange Rate Effect fell 1700.0% to -$18000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$45000.0 through Dec 2025, up 29.69% year-over-year, with the annual reading at -$44000.0 for FY2025, N/A changed from the prior year.
  • Exchange Rate Effect was -$18000.0 for Q4 2025 at Rein Therapeutics, up from -$26000.0 in the prior quarter.
  • Over five years, Exchange Rate Effect peaked at -$1000.0 in Q4 2024 and troughed at -$63000.0 in Q4 2023.
  • The 3-year median for Exchange Rate Effect is -$22000.0 (2025), against an average of -$27000.0.
  • Year-over-year, Exchange Rate Effect surged 98.41% in 2024 and then tumbled 1700.0% in 2025.
  • A 3-year view of Exchange Rate Effect shows it stood at -$63000.0 in 2023, then surged by 98.41% to -$1000.0 in 2024, then tumbled by 1700.0% to -$18000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Exchange Rate Effect are -$18000.0 (Q4 2025), -$26000.0 (Q3 2025), and -$1000.0 (Q4 2024).